Feature | September 30, 2013

Novel MR-guided Radiation Therapy Platform Highlighted at ASTRO

varian, varian medical systems, truebeam, true beam

Varian TrueBeam

September 30, 2013 – IMRIS Inc. and Varian Medical Systems presented data at the American Society for Radiation Oncology (ASTRO) Annual Meeting demonstrating the potential to direct state-of-the-art radiation treatments using diagnostic-quality magnetic resonance (MR) images at each treatment session.

In a presentation to radiation oncology clinicians from around the globe, David Jaffray, Ph.D., radiation physicist at the Princess Margaret Cancer Centre and Director of the Techna Institute at the University Health Network (UHN) in Toronto, described a dedicated MR-guided radiation therapy suite that will allow a MR scanner mounted on ceiling rails to perform MR-guided brachytherapy and external beam radiation delivery. Currently being installed at his institution, this combination is a joint development combining IMRIS' MR imaging with Varian's TrueBeam system for image-guided radiotherapy and radiosurgery.

"Tightly integrating MR imaging with treatment is expected to allow us to increase the accuracy of radiation delivery and pursue research in the emerging field of adaptive radiation therapy — the next level of image-guided radiotherapy that seeks to modify the treatment in response to changes in patient anatomy," said Jaffray. The team at the Princess Margaret has been performing research on the use of MR in radiation therapy as well as studying how the MR and radiation treatment technologies can be made compatible.

"While it is premature to speak to the clinical benefits of the development," he added, "the technical advantage of enhanced visualization of the tumor and normal tissues at the time of treatment opens many possibilities." The Princess Margaret team is planning to explore the system's use in the treatment of prostate, gynecological, and liver cancers, he said.

IMRIS and Varian are co-developing the MR-guided radiation therapy system that combines IMRIS's proprietary MR imaging technology with Varian's TrueBeam system to enable the use of MR imaging during radiotherapy treatments for cancer. The two companies are collaborating with the team at The Princess Margaret Cancer Centre and UHN's Techna Institute in Toronto to develop the system, which is not cleared for sale in any jurisdiction at this time.

For more information: www.varian.com

Related Content

ASTRO Issues Clinical Guideline for Whole Breast Radiation Therapy
News | Radiation Therapy | March 12, 2018
The American Society for Radiation Oncology (ASTRO) today issued a new clinical guideline for the use of whole breast...
Siemens Healthineers Launches New Partners for Digital Ecosystem at HIMSS 2018
News | PACS Accessories | March 12, 2018
At the 2018 Healthcare Information and Management Systems Society (HIMSS) Annual Conference and Exhibition, March 5-9...
Alternative Technique Can Improve Brain Imaging for Restless Children
News | Pediatric Imaging | March 08, 2018
March 8, 2018 – Children often find it difficult to remain still for...
The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain.

This figure shows two different brains that are aligned to a common template space for comparison. The yellow in the anterolateral entorhinal cortex of the young brain indicates significant activity, something that is absent in the older brain. CREDIT: Zachariah Reagh

News | Nuclear Imaging | March 08, 2018
As we get older, it's not uncommon to experience "senior moments," in which we forget where we parked our car or call...
Imaging Plays Key Role in Evaluating Injuries at Olympics
News | Orthopedic Imaging | February 28, 2018
The Olympic Games give elite athletes a chance at athletic triumph, but also carry a risk of injury. When injuries...
MD Anderson and RaySearch Partner to Advance Adaptive Radiation Therapy
News | Treatment Planning | February 26, 2018
The University of Texas MD Anderson Cancer Center and RaySearch Laboratories announced a new strategic alliance with...
Mirada Medical Releases DLCExpert for Radiotherapy Treatment Planning
Technology | Treatment Planning | February 22, 2018
February 22, 2018 — U.K.-based medical imaging software provider Mirada Medical has released DLCExpert, the first com
FDA Clears Siemens Healthineers' GOKnee3D MRI Application
Technology | Magnetic Resonance Imaging (MRI) | February 19, 2018
The U.S. Food and Drug Administration (FDA) has cleared GOKnee3D, a magnetic resonance imaging (MRI) application from...
Mitchell Cancer Institute Selects RayStation for TomoTherapy Planning
News | Treatment Planning | February 16, 2018
The University of South Alabama Mitchell Cancer Institute (MCI) in Mobile, Ala., has selected RayStation as its...
A brain MRI. Gadolinium contrast agents (GBCAs) are partly retained in the brain, raising safety concerns.
Feature | Magnetic Resonance Imaging (MRI) | February 16, 2018 | Dave Fornell
One of the biggest concerns in radiology in recent years is the safety of gadolinium-based contrast agents (GBCAs) us
Overlay Init